^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Biliary Tract Cancer

    Related cancers:
    3d
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Active, not recruiting, Compass Therapeutics | Completed --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    4d
    Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=124, Recruiting, Air Force Military Medical University, China
    New P2 trial • Real-world evidence
    |
    cisplatin • gemcitabine • AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    5d
    Feasibility of Comprehensive Genomic Profiling for Biliary Tract Cancer Using Transpapillary Biopsy Samples: A Prospective Study. (PubMed, J Hepatobiliary Pancreat Sci)
    Introducer-assisted multipass TPB may increase the rate of obtaining adequate CGP specimens, but its suitability remains limited and strongly panel dependent. Since FF samples have better DNA quality, establishing a system detailing their use is desirable.
    Journal
    |
    FoundationOne® CDx • OncoGuide™ NCC Oncopanel System
    5d
    Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study (clinicaltrials.gov)
    P4, N=160, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting | Phase classification: P2 --> P4
    Enrollment open • Phase classification
    5d
    Extracellular RNA Markers of Liver Disease and Cancer (clinicaltrials.gov)
    P=N/A, N=1865, Terminated, Mayo Clinic | Active, not recruiting --> Terminated; Ran out of funds
    Trial termination
    6d
    NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=81, Not yet recruiting, NextPoint Therapeutics, Inc.
    New P1 trial
    |
    HHLA2 (HERV-H LTR-Associating 2)
    6d
    Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | N=70 --> 37 | Trial completion date: Oct 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • nilvanstomig (ZG005)
    9d
    Accurate detection of cholangiocarcinoma in primary sclerosing cholangitis by DNA methylation biomarkers in bile and plasma. (PubMed, JHEP Rep)
    Four DNA methylation biomarkers accurately discriminate CCA from PSC in bile, with lower performance in plasma. Their ability to detect CCA months before clinical diagnosis supports further evaluation in prospective studies to enable earlier, potentially curative intervention in PSC.
    Journal
    |
    PRKCB (Protein Kinase C Beta)
    10d
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Completed, Compass Therapeutics | Active, not recruiting --> Completed | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    10d
    HERIZON-BTC-302: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=286, Recruiting, Jazz Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • Ziihera (zanidatamab-hrii)
    11d
    A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | N=232 --> 1100
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)